Susceptibility patterns and cross resistances of antibiotics against Pseudomonas aeruginosa in a teaching hospital of Turkey

被引:26
作者
Gençer S. [1 ]
Ak O. [1 ]
Benzonana N. [1 ]
Batirel A. [1 ]
Özer S. [1 ]
机构
[1] Dept. Infect. Dis./Clin. Microbiol., K. Dr. Lutfi Kirdar Train./Res. Hosp, Istanbul
关键词
Ceftazidime; Amikacin; Imipenem; Meropenem; Cefepime;
D O I
10.1186/1476-0711-1-2
中图分类号
学科分类号
摘要
Background: Pseudomonas aeruginosa is the third most common pathogen responsible for nosocomial infections and the prevalence of multiple resistant isolates has been increasing. Ninety-nine clinical isolates were studied in order to assess the current levels of susceptibility and cross-resistances of widely used antipseudomonal antibiotics against P. aeruginosa and to determine some resistance mechanisms by phenotypic methods. Methods: MICs of isolates for nine antipseudomonal antibiotics were determined by the E test method. Results: Thirty-six percent of isolates were resistant to more than one group of antibiotics. The rates of susceptible isolates were ciprofloxacin 75%, amikacin 73%, ceftazidime 65%, meropenem 63%, imipenem 63%, piperacillin/tazobactam 60%, cefoperazone/sulbactam 59%, cefepime 54% and tobramycin 44%. The majority of carbapenem resistant isolates were susceptible to ciprofloxacin and amikacin. Conclusion: Ciprofloxacin seems to be the most active agent against P. aeruginosa followed by amikacin in our unit. The usefulness of combinations of these antibiotics and β-lactams should be tested in treating multi-drug resistant P. aeruginosa. © 2002 Gencar et al; licensee BoiMed Central Ltd.
引用
收藏
页数:4
相关论文
共 19 条
[1]  
Gencer S., Benzonana N., Ozer S., Kuzu A., Ozyurt Y., Cerrahi Yoǧun Bak m Ünitesinden izole edilen bakteriler ve antibiyotik duyarl l klar, Yoǧun Bak M Dergisi, 1, pp. 131-137, (2001)
[2]  
Performance Standards for Antimicrobial Susceptibility Testing
[3]  
Eight Informational Supplement M100-S8, (1998)
[4]  
Sanders C.C., Sanders W.E., β-lactam resistance in gram-negative bacteria: Global trends and clinical impact, Clin. Infect. Dis., 15, pp. 824-839, (1992)
[5]  
Livermore D.M., β-lactamases in laboratory and clinical resistance, Clin. Microbiol. Rev., 8, pp. 567-584, (1995)
[6]  
Lee K., Chong Y., Shin H.B., Kim Y.A., Yong D., Yum J.H., Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobacter species, Clin. Microbiol. Infect., 7, pp. 88-91, (2001)
[7]  
Hancock R.E.W., Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria, Clin. Infect. Dis., 27, SUPPL. 1, (1998)
[8]  
Livermore D.M., Of Pseudomonas, porins, pumps and carbapenems, J. Antimicrob. Chemother., 47, pp. 247-250, (2001)
[9]  
Livermore D.M., Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare?, Clin. Infect. Dis., 34, pp. 634-640, (2002)
[10]  
Nordman P., Guibert M., Extended-spectrum β-lactamases in Pseudomonas aeruginosa, J. Antimicrob. Chemother., 42, pp. 128-132, (2001)